O	0	10	Prognostic	Prognostic	JJ	B-NP
O	11	16	value	value	NN	I-NP
O	17	19	of	of	IN	B-PP
O	20	32	angiogenesis	angiogenesis	NN	B-NP
O	33	35	in	in	IN	B-PP
O	36	44	operable	operable	JJ	B-NP
B-Cancer	45	48	non	non	AFX	I-NP
I-Cancer	48	49	-	-	HYPH	I-NP
I-Cancer	49	54	small	small	JJ	B-NP
I-Cancer	55	59	cell	cell	NN	I-NP
I-Cancer	60	64	lung	lung	NN	I-NP
I-Cancer	65	71	cancer	cancer	NN	I-NP
O	71	72	.	.	.	O

B-Cancer	73	79	Tumour	Tumour	NN	B-NP
O	80	92	angiogenesis	angiogenesis	NN	I-NP
O	93	95	is	be	VBZ	B-VP
O	96	98	an	an	DT	B-NP
O	99	108	important	important	JJ	I-NP
O	109	115	factor	factor	NN	I-NP
O	116	119	for	for	IN	B-PP
B-Cancer	120	126	tumour	tumour	NN	B-NP
O	127	133	growth	growth	NN	I-NP
O	134	137	and	and	CC	I-NP
O	138	148	metastasis	metastasis	NN	I-NP
O	148	149	.	.	.	O

O	150	158	Although	Although	IN	B-SBAR
O	159	163	some	some	DT	B-NP
O	164	170	recent	recent	JJ	I-NP
O	171	178	reports	report	NNS	I-NP
O	179	186	suggest	suggest	VBP	B-VP
O	187	191	that	that	IN	B-SBAR
B-Tissue	192	203	microvessel	microvessel	NN	B-NP
O	204	210	counts	count	NNS	I-NP
O	211	213	in	in	IN	B-PP
B-Cancer	214	217	non	non	AFX	B-NP
I-Cancer	217	218	-	-	HYPH	I-NP
I-Cancer	218	223	small	small	JJ	B-NP
I-Cancer	224	228	cell	cell	NN	I-NP
I-Cancer	229	233	lung	lung	NN	I-NP
I-Cancer	234	240	cancer	cancer	NN	I-NP
O	241	244	are	be	VBP	B-VP
O	245	252	related	relate	VBN	I-VP
O	253	255	to	to	TO	B-PP
O	256	257	a	a	DT	B-NP
O	258	262	poor	poor	JJ	I-NP
O	263	270	disease	disease	NN	I-NP
O	271	278	outcome	outcome	NN	I-NP
O	278	279	,	,	,	O
O	280	283	the	the	DT	B-NP
O	284	291	results	result	NNS	I-NP
O	292	296	were	be	VBD	B-VP
O	297	300	not	not	RB	O
O	301	311	conclusive	conclusive	JJ	B-ADJP
O	312	315	and	and	CC	O
O	316	320	were	be	VBD	B-VP
O	321	324	not	not	RB	I-VP
O	325	333	compared	compare	VBN	I-VP
O	334	338	with	with	IN	B-PP
O	339	344	other	other	JJ	B-NP
O	345	354	molecular	molecular	JJ	I-NP
O	355	365	prognostic	prognostic	JJ	I-NP
O	366	373	markers	marker	NNS	I-NP
O	373	374	.	.	.	O

O	375	377	In	In	IN	B-PP
O	378	381	the	the	DT	B-NP
O	382	389	present	present	JJ	I-NP
O	390	395	study	study	NN	I-NP
O	395	396	,	,	,	O
O	397	400	the	the	DT	B-NP
B-Multi-tissue_structure	401	409	vascular	vascular	JJ	I-NP
O	410	415	grade	grade	NN	I-NP
O	416	419	was	be	VBD	B-VP
O	420	428	assessed	assess	VBN	I-VP
O	429	431	in	in	IN	B-PP
O	432	435	107	107	CD	B-NP
O	436	437	(	(	(	O
O	437	439	T1	T1	NN	B-NP
O	439	440	,	,	,	O
O	440	441	2	2	CD	B-NP
O	441	442	-	-	HYPH	I-NP
O	442	444	N0	N0	NN	I-NP
O	444	445	,	,	,	O
O	445	446	1	1	LS	B-LST
O	446	447	)	)	)	O
O	448	456	operable	operable	JJ	B-ADJP
B-Cancer	457	460	non	non	AFX	O
I-Cancer	460	461	-	-	HYPH	O
I-Cancer	461	466	small	small	JJ	B-NP
I-Cancer	467	471	cell	cell	NN	I-NP
I-Cancer	472	476	lung	lung	NN	I-NP
I-Cancer	477	487	carcinomas	carcinoma	NNS	I-NP
O	487	488	,	,	,	O
O	489	494	using	use	VBG	B-VP
O	495	498	the	the	DT	B-NP
O	499	503	JC70	JC70	NN	I-NP
O	504	514	monoclonal	monoclonal	JJ	I-NP
O	515	523	antibody	antibody	NN	I-NP
O	524	526	to	to	TO	B-PP
O	527	531	CD31	CD31	NN	B-NP
O	531	532	.	.	.	O

O	533	538	Three	Three	CD	B-NP
B-Multi-tissue_structure	539	547	vascular	vascular	JJ	I-NP
O	548	554	grades	grade	NNS	I-NP
O	555	559	were	be	VBD	B-VP
O	560	567	defined	define	VBN	I-VP
O	568	572	with	with	IN	B-PP
O	573	582	appraisal	appraisal	NN	B-NP
O	583	585	by	by	IN	B-PP
B-Organ	586	589	eye	eye	NN	B-NP
O	590	593	and	and	CC	B-PP
O	594	596	by	by	IN	B-PP
O	597	605	Chalkley	Chalkley	NNP	B-NP
O	606	614	counting	counting	NN	I-NP
O	614	615	:	:	:	O
O	616	620	high	high	JJ	B-ADJP
O	621	622	(	(	(	O
O	622	630	Chalkley	Chalkley	NNP	B-NP
O	631	636	score	score	NN	I-NP
O	637	638	7	7	CD	I-NP
O	638	639	-	-	HYPH	B-NP
O	639	641	12	12	CD	I-NP
O	641	642	)	)	)	O
O	642	643	,	,	,	O
O	644	650	medium	medium	NN	B-NP
O	651	652	(	(	(	O
O	652	653	5	5	CD	B-NP
O	653	654	-	-	HYPH	I-NP
O	654	655	6	6	CD	I-NP
O	655	656	)	)	)	O
O	656	657	,	,	,	O
O	658	661	and	and	CC	O
O	662	665	low	low	JJ	B-ADJP
O	666	667	(	(	(	O
O	667	668	2	2	CD	B-NP
O	668	669	-	-	HYPH	I-NP
O	669	670	4	4	CD	I-NP
O	670	671	)	)	)	O
O	671	672	.	.	.	O

O	673	678	There	There	EX	B-NP
O	679	682	was	be	VBD	B-VP
O	683	684	a	a	DT	B-NP
O	685	696	significant	significant	JJ	I-NP
O	697	708	correlation	correlation	NN	I-NP
O	709	716	between	between	IN	B-PP
B-Organ	717	720	eye	eye	NN	B-NP
O	721	730	appraisal	appraisal	NN	I-NP
O	731	734	and	and	CC	O
O	735	743	Chalkley	Chalkley	NNP	B-NP
O	744	752	counting	counting	NN	I-NP
O	753	754	(	(	(	O
O	754	755	P	P	NN	B-NP
O	757	761	less	less	JJR	B-NP
O	762	766	than	than	IN	I-NP
O	768	769	0	0	CD	I-NP
O	769	770	.	.	.	I-NP
O	770	774	0001	0001	CD	I-NP
O	774	775	)	)	)	O
O	775	776	.	.	.	O

B-Multi-tissue_structure	777	785	Vascular	Vascular	JJ	B-NP
O	786	791	grade	grade	NN	I-NP
O	792	795	was	be	VBD	B-VP
O	796	799	not	not	RB	O
O	800	807	related	related	JJ	B-ADJP
O	808	810	to	to	TO	B-PP
O	811	820	histology	histology	NN	B-NP
O	820	821	,	,	,	O
O	822	827	grade	grade	NN	B-NP
O	827	828	,	,	,	O
O	829	842	proliferation	proliferation	NN	B-NP
O	843	848	index	index	NN	I-NP
O	849	850	(	(	(	O
O	850	854	Ki67	Ki67	NN	B-NP
O	854	855	)	)	)	O
O	855	856	,	,	,	O
O	857	859	or	or	CC	O
O	860	864	EGFR	EGFR	NN	B-NP
O	865	867	or	or	CC	O
O	868	871	p53	p53	NN	B-NP
O	872	882	expression	expression	NN	I-NP
O	882	883	.	.	.	O

B-Cancer	884	891	Tumours	Tumour	NNS	B-NP
O	892	896	from	from	IN	B-PP
O	897	904	younger	young	JJR	B-NP
O	905	913	patients	patient	NNS	I-NP
O	914	917	had	have	VBD	B-VP
O	918	919	a	a	DT	B-NP
O	920	926	higher	high	JJR	I-NP
O	927	932	grade	grade	NN	I-NP
O	933	935	of	of	IN	B-PP
O	936	948	angiogenesis	angiogenesis	NN	B-NP
O	949	950	(	(	(	O
O	950	951	P	P	NN	B-NP
O	952	953	=	=	SYM	B-VP
O	954	955	0	0	CD	B-NP
O	955	956	.	.	SYM	I-NP
O	956	958	05	05	CD	I-NP
O	958	959	)	)	)	O
O	959	960	.	.	.	O

O	961	966	Apart	Apart	RB	B-ADVP
O	967	971	from	from	IN	B-PP
O	972	975	the	the	DT	B-NP
B-Multi-tissue_structure	976	984	vascular	vascular	JJ	I-NP
O	985	990	grade	grade	NN	I-NP
O	990	991	,	,	,	O
O	992	996	none	none	NN	B-NP
O	997	999	of	of	IN	B-PP
O	1000	1003	the	the	DT	B-NP
O	1004	1009	other	other	JJ	I-NP
O	1010	1017	factors	factor	NNS	I-NP
O	1018	1026	examined	examine	VBN	B-VP
O	1027	1030	was	be	VBD	B-VP
O	1031	1044	statistically	statistically	RB	I-VP
O	1045	1052	related	relate	VBN	I-VP
O	1053	1055	to	to	TO	B-PP
B-Multi-tissue_structure	1056	1061	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1062	1066	node	node	NN	I-NP
O	1067	1077	metastasis	metastasis	NN	I-NP
O	1078	1079	(	(	(	O
O	1079	1080	P	P	NN	B-NP
O	1082	1086	less	less	JJR	B-NP
O	1087	1091	than	than	IN	I-NP
O	1093	1094	0	0	CD	I-NP
O	1094	1095	.	.	.	I-NP
O	1095	1099	0001	0001	CD	I-NP
O	1099	1100	)	)	)	O
O	1100	1101	.	.	.	O

O	1102	1103	A	A	DT	B-NP
O	1104	1114	univariate	univariate	JJ	I-NP
O	1115	1123	analysis	analysis	NN	I-NP
O	1124	1126	of	of	IN	B-PP
O	1127	1135	survival	survival	NN	B-NP
O	1136	1142	showed	show	VBD	B-VP
O	1143	1147	that	that	IN	B-SBAR
B-Multi-tissue_structure	1148	1156	vascular	vascular	JJ	B-NP
O	1157	1162	grade	grade	NN	I-NP
O	1163	1166	was	be	VBD	B-VP
O	1167	1170	the	the	DT	B-NP
O	1171	1175	most	most	RBS	I-NP
O	1176	1187	significant	significant	JJ	I-NP
O	1188	1198	prognostic	prognostic	JJ	I-NP
O	1199	1205	factor	factor	NN	I-NP
O	1206	1207	(	(	(	O
O	1207	1208	P	P	NN	B-NP
O	1209	1210	=	=	SYM	B-VP
O	1211	1212	0	0	CD	B-NP
O	1212	1213	.	.	SYM	I-NP
O	1213	1217	0004	0004	CD	I-NP
O	1217	1218	)	)	)	O
O	1218	1219	,	,	,	O
O	1220	1228	followed	follow	VBN	B-VP
O	1229	1231	by	by	IN	B-PP
O	1232	1233	N	N	NN	B-NP
O	1233	1234	-	-	HYPH	O
O	1234	1239	stage	stage	NN	B-NP
O	1240	1241	(	(	(	O
O	1241	1242	P	P	NN	B-NP
O	1243	1244	=	=	SYM	B-VP
O	1245	1246	0	0	CD	B-NP
O	1246	1247	.	.	SYM	I-NP
O	1247	1250	001	001	CD	I-NP
O	1250	1251	)	)	)	O
O	1251	1252	.	.	.	O

O	1253	1255	In	In	IN	B-PP
O	1256	1257	a	a	DT	B-NP
O	1258	1270	multivariate	multivariate	JJ	I-NP
O	1271	1279	analysis	analysis	NN	I-NP
O	1279	1280	,	,	,	O
O	1281	1282	N	N	NN	B-NP
O	1282	1283	-	-	HYPH	B-NP
O	1283	1288	stage	stage	NN	I-NP
O	1289	1292	and	and	CC	O
B-Multi-tissue_structure	1293	1301	vascular	vascular	JJ	B-NP
O	1302	1307	grade	grade	NN	I-NP
O	1308	1312	were	be	VBD	B-VP
O	1313	1316	not	not	RB	I-VP
O	1317	1322	found	find	VBN	I-VP
O	1323	1325	to	to	TO	I-VP
O	1326	1328	be	be	VB	I-VP
O	1329	1340	independent	independent	JJ	B-NP
O	1341	1351	prognostic	prognostic	JJ	I-NP
O	1352	1359	factors	factor	NNS	I-NP
O	1359	1360	,	,	,	O
O	1361	1366	since	since	IN	B-SBAR
O	1367	1371	they	they	PRP	B-NP
O	1372	1376	were	be	VBD	B-VP
O	1377	1385	strongly	strongly	RB	I-VP
O	1386	1393	related	relate	VBN	I-VP
O	1394	1396	to	to	TO	B-PP
O	1397	1401	each	each	DT	B-NP
O	1402	1407	other	other	JJ	I-NP
O	1407	1408	.	.	.	O

O	1409	1418	Excluding	Exclude	VBG	B-PP
O	1419	1420	N	N	NN	B-NP
O	1420	1421	-	-	HYPH	I-NP
O	1421	1426	stage	stage	NN	I-NP
O	1426	1427	,	,	,	O
B-Multi-tissue_structure	1428	1436	vascular	vascular	JJ	B-NP
O	1437	1442	grade	grade	NN	I-NP
O	1443	1446	was	be	VBD	B-VP
O	1447	1450	the	the	DT	B-NP
O	1451	1455	only	only	JJ	I-NP
O	1456	1467	independent	independent	JJ	I-NP
O	1468	1478	prognostic	prognostic	JJ	I-NP
O	1479	1485	factor	factor	NN	I-NP
O	1486	1487	(	(	(	O
O	1487	1488	P	P	NN	B-NP
O	1489	1490	=	=	SYM	B-VP
O	1491	1492	0	0	CD	B-NP
O	1492	1493	.	.	SYM	I-NP
O	1493	1496	007	007	CD	I-NP
O	1496	1497	)	)	)	O
O	1497	1498	.	.	.	O

O	1499	1505	Kaplan	Kaplan	NNP	B-NP
O	1505	1506	-	-	HYPH	I-NP
O	1506	1511	Meier	Meier	NNP	I-NP
O	1512	1520	survival	survival	NN	I-NP
O	1521	1527	curves	curve	NNS	I-NP
O	1528	1534	showed	show	VBD	B-VP
O	1535	1536	a	a	DT	B-NP
O	1537	1550	statistically	statistically	RB	I-NP
O	1551	1562	significant	significant	JJ	I-NP
O	1563	1568	worse	worse	JJR	I-NP
O	1569	1578	prognosis	prognosis	NN	I-NP
O	1579	1582	for	for	IN	B-PP
O	1583	1591	patients	patient	NNS	B-NP
O	1592	1596	with	with	IN	B-PP
O	1597	1601	high	high	JJ	B-NP
B-Multi-tissue_structure	1602	1610	vascular	vascular	JJ	I-NP
O	1611	1616	grade	grade	NN	I-NP
O	1616	1617	,	,	,	O
O	1618	1621	but	but	CC	O
O	1622	1624	no	no	DT	B-NP
O	1625	1635	difference	difference	NN	I-NP
O	1636	1639	was	be	VBD	B-VP
O	1640	1648	observed	observe	VBN	I-VP
O	1649	1656	between	between	IN	B-PP
O	1657	1660	low	low	JJ	B-NP
O	1661	1664	and	and	CC	I-NP
O	1665	1671	medium	medium	JJ	I-NP
B-Multi-tissue_structure	1672	1680	vascular	vascular	JJ	I-NP
O	1681	1686	grade	grade	NN	I-NP
O	1686	1687	.	.	.	O

O	1688	1693	These	These	DT	B-NP
O	1694	1698	data	datum	NNS	I-NP
O	1699	1706	suggest	suggest	VBP	B-VP
O	1707	1711	that	that	IN	B-SBAR
O	1712	1724	angiogenesis	angiogenesis	NN	B-NP
O	1725	1727	in	in	IN	B-PP
O	1728	1736	operable	operable	JJ	B-NP
B-Cancer	1737	1740	non	non	AFX	I-NP
I-Cancer	1740	1741	-	-	HYPH	I-NP
I-Cancer	1741	1746	small	small	JJ	B-NP
I-Cancer	1747	1751	cell	cell	NN	I-NP
I-Cancer	1752	1756	lung	lung	NN	I-NP
I-Cancer	1757	1763	cancer	cancer	NN	I-NP
O	1764	1766	is	be	VBZ	B-VP
O	1767	1768	a	a	DT	B-NP
O	1769	1774	major	major	JJ	I-NP
O	1775	1785	prognostic	prognostic	JJ	I-NP
O	1786	1792	factor	factor	NN	I-NP
O	1793	1796	for	for	IN	B-PP
O	1797	1805	survival	survival	NN	B-NP
O	1806	1809	and	and	CC	O
O	1809	1810	,	,	,	O
O	1811	1816	among	among	IN	B-PP
O	1817	1820	the	the	DT	B-NP
O	1821	1831	parameters	parameter	NNS	I-NP
O	1832	1838	tested	test	VBN	B-VP
O	1838	1839	,	,	,	O
O	1840	1842	is	be	VBZ	B-VP
O	1843	1846	the	the	DT	B-NP
O	1847	1851	only	only	JJ	I-NP
O	1852	1858	factor	factor	NN	I-NP
O	1859	1866	related	related	JJ	B-ADJP
O	1867	1869	to	to	TO	B-PP
B-Cell	1870	1876	cancer	cancer	NN	B-NP
I-Cell	1877	1881	cell	cell	NN	I-NP
O	1882	1891	migration	migration	NN	I-NP
O	1892	1894	to	to	TO	B-PP
B-Multi-tissue_structure	1895	1900	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1901	1906	nodes	node	NNS	I-NP
O	1906	1907	.	.	.	O

O	1908	1911	The	The	DT	B-NP
O	1912	1923	integration	integration	NN	I-NP
O	1924	1926	of	of	IN	B-PP
B-Multi-tissue_structure	1927	1935	vascular	vascular	JJ	B-NP
O	1936	1943	grading	grading	NN	I-NP
O	1944	1946	in	in	IN	B-PP
O	1947	1955	clinical	clinical	JJ	B-NP
O	1956	1962	trials	trial	NNS	I-NP
O	1963	1965	on	on	IN	B-PP
O	1966	1974	adjuvant	adjuvant	JJ	B-NP
O	1975	1987	chemotherapy	chemotherapy	NN	I-NP
O	1988	1991	and	and	CC	O
O	1991	1992	/	/	SYM	B-NP
O	1992	1994	or	or	CC	O
O	1995	2007	radiotherapy	radiotherapy	NN	B-NP
O	2008	2013	could	could	MD	B-VP
O	2014	2027	substantially	substantially	RB	I-VP
O	2028	2038	contribute	contribute	VB	I-VP
O	2039	2041	in	in	IN	B-PP
O	2042	2050	defining	define	VBG	B-VP
O	2051	2057	groups	group	NNS	B-NP
O	2058	2060	of	of	IN	B-PP
O	2061	2069	operable	operable	JJ	B-NP
O	2070	2078	patients	patient	NNS	I-NP
O	2079	2082	who	who	WP	B-NP
O	2083	2088	might	might	MD	B-VP
O	2089	2096	benefit	benefit	VB	I-VP
O	2097	2101	from	from	IN	B-PP
O	2102	2111	cytotoxic	cytotoxic	JJ	B-NP
O	2112	2121	treatment	treatment	NN	I-NP
O	2121	2122	.	.	.	O

